Testing a clot-busting drug coated with platelet membranes
Part of Blood & lymphatic, Heart & circulation clinical trials.
This study tests a new way to deliver a clot-dissolving drug called tenecteplase. The drug is coated with platelet membranes to target blood clots in arteries. It may offer a safer, more effective treatment for heart attack patients and is also enrolling healthy volunteers for comparison.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and weigh at least 99 pounds (45 kg).
- For people with heart disease: You are scheduled for a heart catheterization and have been taking aspirin and ticagrelor for at least 3 days, or had a high dose at least 12 hours before.
- For healthy volunteers: You are not taking any medications that affect bleeding, such as blood thinners or ibuprofen.
- You must not have diabetes (for healthy volunteers) or be a smoker (for healthy volunteers).
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a clot-dissolving drug called tenecteplase can improve recovery for people who had a large-vessel ischemic stroke 4.5 to 24 hours earlier and can’t have a mechanical clot removal procedure in time. If you join, you’ll get either tenecteplase or standard medical care, and the study will track your recovery and safety.
This trial tests whether a stronger clot-busting drug (tenecteplase) is safe and works for people who have had a stroke while taking a common blood thinner. If you qualify, you may get this treatment within a few hours of your stroke to help improve recovery.
This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the brain artery after a successful mechanical clot removal can improve recovery for people with a certain type of stroke. The goal is to see if it safely helps clear any remaining tiny clots and reduces disability.
This trial tests whether giving a clot-busting medication (tenecteplase) directly into the artery after an incomplete clot-removal procedure can improve blood flow and outcomes in people with large vessel strokes. It aims to help those who had partial reopening after mechanical thrombectomy.
This study tests a clot-dissolving drug called tenecteplase given directly into the artery after a mechanical thrombectomy (clot removal). The goal is to see if it helps improve blood flow to the small vessels in the brain after the main clot is removed.
Hear when a new Arterial Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.